参芪扶正注射液联合TP方案治疗卵巢癌的临床分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Shenqi Fuzheng Injection combined with TP regimen in the treatment of ovarian cancer.Methods From February 2013 to January 2016,clinical data of 50 patients with ovarian cancer treated in our hospital were retrospectively analyzed and patients were divided into the observation group(n=25) and the control group(n=25)according to clinical data of patients.Both groups were treated with Taxol and Platinum(TP regimen).On the basis,the observation group was treated with Shenqi Fuzheng Injection,intravenous drip of 250 ml Shenqi Fuzheng Injection,once a time,and 3 weeks was a cycle.The efficacy of treatment,quality of life(KPS)and the incidence of adverse reactions were compared between two groups.Results There was no significant difference in the total effective rate and disease control rate between the two groups(P＞0.05).The improvement rate of KPS score in the observation group was 96.0%while in the control group was 72.0%,and there was a statistical difference between two groups(P＜0.05).The incidence rate of leukopenia,hair loss,bone marrow suppression,vomiting and nausea,gastrointestinal reactions and other adverse reactions in the observation group were lower than those in the control group,the differences were statistically significant(P＜0.05).Conclusion The clinical effect of Shenqi Fuzheng Injection combined with TP regimen is significantin the treatment of ovarian cancer.It can significantly improve the quality of life of patients,reduce the adverse reactions caused by chemotherapy,and improve patients′tolerance to drugs,which has positive effect on the prognosis of patients,it is worthy of clinical prumotion an application.

Key words： Shenqi Fuzheng Injection TP regimen Ovarian cancer Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Cong
	FENG Xiao-li

Cite this article:

YU Cong,FENG Xiao-li. Clinical analysis of Shenqi Fuzheng Injection combined with TP regimen in the treatment of ovarian cancer[J]. 中国当代医药, 2017, 24(8): 63-65.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I8/63

[1]	张爽爽，夏庆民，郑荣寿，等.中国2010年卵巢癌发病与死亡分析[J].中国肿瘤，2016，25（3）：169-173.
[2]	沈剑钦.紫杉醇联合卡铂治疗晚期卵巢癌的临床疗效观察[J].中国医学工程，2013，21（12）：68.
[3]	刘怀民，杨峰，刘晓莉，等.参芪扶正注射液联合化疗治疗恶性肿瘤临床研究[J].中医学报，2011，26（11）：1284-1286.
[4]	朱熠，张国楠.卵巢癌、输卵管癌和腹膜癌FIGO2013分期和临床意义的解读[J].肿瘤预防与治疗，2015，28（5）：291-294.
[5]	杨旭，许光，雷振，等.RECIST1.1与WHO、RECIST1.0标准评价周边型肺癌疗效比较[J].中国医学影像学杂志，2012，20（5）：355-358.
[6]	饶阳，曲芃芃.卵巢癌患者生活质量的研究[J].国际妇产科学杂志，2014，41（3）：244-246.
[7]	张彦.肿瘤标记物用于卵巢癌早期诊断的研究进展[J].国际妇产科学杂志，2012，39（2）：148-151.
[8]	梁铭霖，王泽华.卵巢癌的筛查和早期诊断[J].中国实用妇科与产科杂志，2012，28（3）：166-168.
[9]	张孟伟，秦亚光，王亚秋，等.铂类耐药复发转移性卵巢癌贝伐单抗联合白蛋白结合型紫杉醇治疗临床观察[J].中华肿瘤防治杂志，2016，23（5）：331-334.
[10]	张蓉，李斌，白萍，等.紫杉醇联合铂类在局部晚期宫颈癌新辅助化疗中的应用[J].中华肿瘤杂志，2011，33（8）：616-620.
[11]	叶冬云.紫杉醇联合顺铂新辅助化疗治疗局部晚期宫颈癌的疗效观察[J].临床和实验医学杂志，2014，13（7）：557-559.
[12]	刘少晓，程晓燕，郑红枫，等.紫杉醇联合顺铂新辅助治疗局部晚期宫颈癌的临床疗效及安全性评价[J].中国临床药理学杂志，2015，31（6）：432-434.
[13]	田树旭，杨隽钧，任彤，等.紫杉醇联合铂类治疗持续耐药及复发性妊娠滋养细胞肿瘤的疗效分析[J].实用妇产科杂志，2014，30（10）：764-767.
[14]	郑永法，徐慧琳，戈伟.参芪扶正注射液联合FolFox4方案与FolFox4方案对晚期胃癌患者疗效影响分析[J].中国医药导报，2014，11（3）：79-82.
[15]	王丽霞，王丽峰.参芪扶正注射液联合紫杉醇和顺铂方案治疗晚期卵巢癌的临床疗效[J].中国肿瘤临床与康复，2015，22（12）：1459-1461.
[16]	焦亦妮，王喜华，彭妍，等.黄芪注射液联合TP化疗方案治疗晚期卵巢癌的临床疗效分析[J].现代生物医学进展，2012，12（27）：5284-5287.